LianBio Contracts & Agreements
73 Contracts & Agreements
- Business Finance (13 contracts)
- Business Operations (10)
- Human Resources (15)
- Intellectual Property (19)
- Real Estate (5)
- Uncategorized (11)
- Description of Securities (Filed With SEC on March 28, 2023)
- Employment Contract and Addendum to Employment Contract, dated as of March 14, 2023, by and between Shanghai LianBio Development Co., Ltd., and Yi Larson (Filed With SEC on March 28, 2023)
- Commercialization Agreement, dated as of December 16, 2022, by and among LianBio Development (HK) Limited, LianBio Respiratory Limited, ReViral Ltd. and Pfizer Inc (Filed With SEC on March 28, 2023)
- Separation Agreement, dated as of December 13, 2022, by and between LianBio and Debra Yu (Filed With SEC on March 28, 2023)
- Consulting Agre (Filed With SEC on March 28, 2023)
- First Amendment to License and Collaboration Agreement, dated as of February 28, 2023 by and between LianBio Respiratory Limited and Landos BioPharma, Inc (Filed With SEC on March 28, 2023)
- License and Collaboration Agreement, dated as of February 28, 2023, by and between LianBio Development (HK) Limited and NImmune Biopharma, Inc (Filed With SEC on March 28, 2023)
- Amendment No. 1 to the License, Development and Commercialization Agreement, dated as of March 16, 2023, by and between Nanobiotix S.A. and Lian Oncology Limited (Filed With SEC on March 28, 2023)
- Amendment No. 1 to License and Collaboration Agreement, dated as of September 26, 2022, by and among LianBio Inflammatory Limited and Lyra Therapeutics, Inc (Filed With SEC on November 10, 2022)
- Amended and Restated Executive Employment Agreement, dated as of September 30, 2021, by and among LianBio, LLC and Yi Larson (Filed With SEC on May 12, 2022)
- Description of (Filed With SEC on March 31, 2022)
- Second Amendment (Filed With SEC on March 31, 2022)
- Assignment and Assumption Agreement related to Pfizer Agreement, dated December 15, 2021, by and among LianBio and LianBio Development (HK) Limited (Filed With SEC on March 31, 2022)
- Amended and Restated Executive Employment Agreement, dated as of September 14, 2021, by and among LianBio, LLC and Yizhe Wang (Filed With SEC on March 31, 2022)
- Form of Non-Performance Based Restricted Share Unit Agreement (Filed With SEC on March 31, 2022)
- Form of Performance Based Restricted Share Unit Agreement (Filed With SEC on March 31, 2022)
- Form of Non-Performance Based Share Option Agreement (Employees) (Filed With SEC on March 31, 2022)
- Form of Performance Based Share Option Agreement (Filed With SEC on March 31, 2022)
- Lease Contract for Office Building of Corporate Avenue dated November 4, 2021, by and between Shanghai Xingqiao Real Estate Co., Ltd. and Shanghai LianBio Development Co., Ltd (Filed With SEC on November 10, 2021)
- Form of Underwriting Agreement (Filed With SEC on October 20, 2021)
- Specimen Certificate evidencing the Ordinary Shares (Filed With SEC on October 20, 2021)
- Form of Warrant to Purchase Ordinary Shares, dated October 18, 2021, issued by LianBio (Filed With SEC on October 20, 2021)
- Option Agreement, dated October 18, 2021, by and among LianBio, LianBio Ophthalmology and Tarsus Pharmaceuticals, Inc (Filed With SEC on October 20, 2021)
- Joinder Agreements to Second Amended and Restated Shareholders Agreement (Filed With SEC on October 20, 2021)
- Warrant to Purchase Ordinary Shares, dated October 18, 2021 issued by LianBio (Filed With SEC on October 20, 2021)
- LianBio Non-Employee Director Compensation Policy, to be in effect upon completion of this offering (Filed With SEC on October 20, 2021)
- Form of Deposit Agreement (Filed With SEC on October 8, 2021)
- Director Nomination Agreement, dated October 8, 2021, by and among LianBio and Perceptive Life Sciences Master Fund, Ltd., LEV LB Holdings, LP, Perceptive Xontogency Venture Fund,... (Filed With SEC on October 8, 2021)
- LianBio 2021 Equity Incentive Plan, to be in effect upon completion of this offering (Filed With SEC on October 8, 2021)
- Form of Non-Statutory Share Option Agreement (Non-Employee Directors) (Filed With SEC on October 8, 2021)
- Form of Non-Statutory Share Option Agreement (Employees) (Filed With SEC on October 8, 2021)
- Form of Restricted Share Unit Agreement (Employees) (Filed With SEC on October 8, 2021)
- LianBio 2021 Cash Incentive Plan, to be in effect upon completion of this offering (Filed With SEC on October 8, 2021)
- Second Amended and Restated Shareholders Agreement dated October 28, 2020, by and among LianBio and the investors party thereto (Filed With SEC on October 1, 2021)
- Information Rights Letter of BridgeBio Pharma LLC, dated October 16, 2019, by and between the Company and BridgeBio Pharma LLC (Filed With SEC on October 1, 2021)
- Amended and Restated Option Agreement, dated as of August 10, 2020, by and among LianBio and MyoKardia, Inc. and QED Therapeutics, Inc (Filed With SEC on October 1, 2021)
- Equity Holders Agreement, dated August 10, 2020, by and among LianBio, Lian Cardiovascular and MyoKardia, Inc (Filed With SEC on October 1, 2021)
- Form of Warrant to Purchase Ordinary Shares, dated October 16, 2019, issued by Lian Oncology (Filed With SEC on October 1, 2021)
- Lian Cardiovascular Warrant to Purchase Ordinary Shares, dated August 10, 2020, issued by Lian Cardiovascular (Filed With SEC on October 1, 2021)
- Exclusive License Agreement, dated August 10, 2020, by and among LianBio, LianBio Licensing LLC and MyoKardia, Inc (Filed With SEC on October 1, 2021)
- Amendment to the Exclusive License Agreement, dated October 8, 2020, by and among LianBio, LianBio Licensing LLC and MyoKardia, Inc (Filed With SEC on October 1, 2021)
- Second Amendment to the Exclusive License Agreement, dated January 4, 2021, by and among LianBio, LianBio Licensing LLC and MyoKardia, Inc (Filed With SEC on October 1, 2021)
- Exclusivity Agreement, dated October 16, 2019, by and between LianBio and BridgeBio Pharma LLC (Filed With SEC on October 1, 2021)
- Exclusive License Agreement, dated October 16, 2019, by and between LianBio and QED Therapeutics, Inc (Filed With SEC on October 1, 2021)
- Amendment to the Exclusive License Agreement, dated September 26, 2020, by and between LianBio and QED Therapeutics, Inc (Filed With SEC on October 1, 2021)
- Novation Agreement, dated October 11, 2020, by and among LianBio, LianBio Licensing LLC and QED Therapeutics, Inc (Filed With SEC on October 1, 2021)
- Exclusive License Agreement, dated August 9, 2020, by and among LianBio, LianBio Licensing LLC and Navire Pharma, Inc (Filed With SEC on October 1, 2021)
- First Amendment to the Exclusive License Agreement, dated September 23, 2020, by and among LianBio, LianBio Licensing LLC and Navire Pharma, Inc (Filed With SEC on October 1, 2021)
- Second Amendment to the Exclusive License Agreement, dated September 28, 2020, by and among LianBio, LianBio Licensing LLC and Navire Pharma, Inc (Filed With SEC on October 1, 2021)
- Third Amendment to the Exclusive License Agreement, dated December 17, 2020, by and among LianBio, LianBio Licensing LLC and Navire Pharma, Inc (Filed With SEC on October 1, 2021)
- Strategic Collaboration Agreement, dated November 17, 2020, by and between LianBio and Pfizer Inc (Filed With SEC on October 1, 2021)
- Development and License Agreement, dated March 26, 2021, by and between LianBio Ophthalmology Limited and Tarsus Pharmaceuticals, Inc (Filed With SEC on October 1, 2021)
- License, Development and Commercialization Agreement, dated May 11, 2021, by and between Nanobiotix S.A. and LianBio Oncology Limited (Filed With SEC on October 1, 2021)
- License and Collaboration Agreement, dated May 14, 2021, by and between LianBio Respiratory Limited and Landos BioPharma, Inc (Filed With SEC on October 1, 2021)
- License and Collaboration Agreement, dated May 31, 2021, by and among LianBio Inflammatory Limited, LianBio and Lyra Therapeutics, Inc (Filed With SEC on October 1, 2021)
- Co-Development and License Agreement, dated March 1, 2021, by and between LianBio Respiratory Limited and ReViral Ltd (Filed With SEC on October 1, 2021)
- Lease and Lease Agreement, dated June 18, 2020, by and between LianBio dba Lian Pharma and Carnegie 103 Associates, LLC (Filed With SEC on October 1, 2021)
- Shanghai Municipality Lease Contract for Premises, dated December 23, 2019, by and between Shanghai LianBio Development Co. Ltd. and Shanghai Pudong Kerry Parkside Real Estate... (Filed With SEC on October 1, 2021)
- Supplemental Agreement II to Lease Contract of Kerry Parkside Office Building, dated as of August 31, 2020, by and between Shanghai Lianbio Development Co. Ltd. and Shanghai... (Filed With SEC on October 1, 2021)
- Form of Indemnification Agreement (Filed With SEC on October 1, 2021)
- Indemnification Agreement, dated October 28, 2020 by and among LianBio, Konstantin Poukalov and Perceptive Life Sciences Master Fund, Ltd., Perceptive Xontogeny Venture Fund, LP,... (Filed With SEC on October 1, 2021)
- Contribution, Assignment and Assumption Agreement, dated as of September 28, 2021, by and among LianBio Licensing, LLC, Lian Cardviovascular, and LianBio relating to the Exclusive... (Filed With SEC on October 1, 2021)
- Contribution, Assignment and Assumption Agreement, dated as of September 28, 2021, by and among Lian Cardviovascular, Lian Cardiovascular Limited and LianBio relating to the... (Filed With SEC on October 1, 2021)
- Contribution, Assignment and Assumption Agreement, dated as of September 28, 2021, by and among LianBio Licensing, LLC, Lian Oncology and LianBio relating to the Exclusive License... (Filed With SEC on October 1, 2021)
- Contribution, Assignment and Assumption Agreement, dated as of September 28, 2021, by and among Lian Oncology, Lian Oncology Limited and LianBio relating to the Exclusive License... (Filed With SEC on October 1, 2021)
- Contribution, Assignment and Assumption Agreement, dated as of September 28, 2021, by and among LianBio Licensing, LLC, Lian Oncology and LianBio relating to the Exclusive License... (Filed With SEC on October 1, 2021)
- Contribution, Assignment and Assumption Agreement, dated as of September 28, 2021, by and among Lian Oncology, Lian Oncology Limited and LianBio relating to the Exclusive License... (Filed With SEC on October 1, 2021)
- Amendment No. 1 to Lease and Lease Agreement, dated as of July 1, 2021, between Carnegie 103 Associates, LLC and LianBio, LLC (Filed With SEC on October 1, 2021)
- Executive Employment Agreement, dated as of September 26, 2019, by and between LianBio and Bing Li (Filed With SEC on October 1, 2021)
- Separation Agreement, dated as of February 24, 2021, by and between LianBio and Bing Li (Filed With SEC on October 1, 2021)
- Amended and Restated Executive Employment Agreement, dated as of September 14, 2021, by and amongLianBio, LianBio, LLC and Debra Yu, M.D (Filed With SEC on October 1, 2021)
- Amended and Restated Executive Employment Agreement, dated as of September 14, 2021, by and among LianBio, LianBio, LLC and Brianne Jahn (Filed With SEC on October 1, 2021)
- LianBio 2019 Equity Incentive Plan (Filed With SEC on October 1, 2021)
